Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza

Korean experiences and perspectives

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Influenza is a major cause of substantial morbidity and mortality in humans every year. Vaccination is the main strategy to prevent influenza infection, but antiviral agents also play an important role in the control of both seasonal and pandemic influenza. During the influenza A/H1N1 pandemic in 2009, early prompt antiviral therapy may have reduced the severity of the influenza outcomes including pneumonia, hospitalization and mortality in the Republic of Korea. Since the 2009 H1N1 pandemic, there have been increasing usages of antiviral agents for the treatment of patients with seasonal influenza. Although currently rare, antiviral resistance among influenza viruses may emerge and increase with increased use of neuraminidase inhibitors. New agents with different modes of action are under investigation, including favipiravir, DAS181, nitazoxanide and broad-spectrum neutralizing monoclonal antibodies. Data are limited with respect to high-dose and combination antiviral therapies. So, clinical trials are warranted to evaluate diverse antiviral combinations that may be synergistic and less likely to induce breakthrough resistance.

Original languageEnglish
Pages (from-to)1361-1372
Number of pages12
JournalExpert Review of Anti-Infective Therapy
Volume13
Issue number11
DOIs
Publication statusPublished - 2015 Nov 2

Fingerprint

Pandemics
Human Influenza
Antiviral Agents
nitazoxanide
Therapeutics
Republic of Korea
Mortality
Neuraminidase
Neutralizing Antibodies
Orthomyxoviridae
Pneumonia
Vaccination
Hospitalization
Monoclonal Antibodies
Clinical Trials
Morbidity
Infection

Keywords

  • Antiviral agents
  • drug resistance
  • epidemics
  • influenza
  • Republic of Korea

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology

Cite this

@article{8606cabb2dd144d2be49bac7387660ab,
title = "Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives",
abstract = "Influenza is a major cause of substantial morbidity and mortality in humans every year. Vaccination is the main strategy to prevent influenza infection, but antiviral agents also play an important role in the control of both seasonal and pandemic influenza. During the influenza A/H1N1 pandemic in 2009, early prompt antiviral therapy may have reduced the severity of the influenza outcomes including pneumonia, hospitalization and mortality in the Republic of Korea. Since the 2009 H1N1 pandemic, there have been increasing usages of antiviral agents for the treatment of patients with seasonal influenza. Although currently rare, antiviral resistance among influenza viruses may emerge and increase with increased use of neuraminidase inhibitors. New agents with different modes of action are under investigation, including favipiravir, DAS181, nitazoxanide and broad-spectrum neutralizing monoclonal antibodies. Data are limited with respect to high-dose and combination antiviral therapies. So, clinical trials are warranted to evaluate diverse antiviral combinations that may be synergistic and less likely to induce breakthrough resistance.",
keywords = "Antiviral agents, drug resistance, epidemics, influenza, Republic of Korea",
author = "Joon-Young Song and Noh, {Ji Yun} and Wonseok Choi and Hee-Jin Cheong and Kim, {Woo Joo}",
year = "2015",
month = "11",
day = "2",
doi = "10.1586/14787210.2015.1076334",
language = "English",
volume = "13",
pages = "1361--1372",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza

T2 - Korean experiences and perspectives

AU - Song, Joon-Young

AU - Noh, Ji Yun

AU - Choi, Wonseok

AU - Cheong, Hee-Jin

AU - Kim, Woo Joo

PY - 2015/11/2

Y1 - 2015/11/2

N2 - Influenza is a major cause of substantial morbidity and mortality in humans every year. Vaccination is the main strategy to prevent influenza infection, but antiviral agents also play an important role in the control of both seasonal and pandemic influenza. During the influenza A/H1N1 pandemic in 2009, early prompt antiviral therapy may have reduced the severity of the influenza outcomes including pneumonia, hospitalization and mortality in the Republic of Korea. Since the 2009 H1N1 pandemic, there have been increasing usages of antiviral agents for the treatment of patients with seasonal influenza. Although currently rare, antiviral resistance among influenza viruses may emerge and increase with increased use of neuraminidase inhibitors. New agents with different modes of action are under investigation, including favipiravir, DAS181, nitazoxanide and broad-spectrum neutralizing monoclonal antibodies. Data are limited with respect to high-dose and combination antiviral therapies. So, clinical trials are warranted to evaluate diverse antiviral combinations that may be synergistic and less likely to induce breakthrough resistance.

AB - Influenza is a major cause of substantial morbidity and mortality in humans every year. Vaccination is the main strategy to prevent influenza infection, but antiviral agents also play an important role in the control of both seasonal and pandemic influenza. During the influenza A/H1N1 pandemic in 2009, early prompt antiviral therapy may have reduced the severity of the influenza outcomes including pneumonia, hospitalization and mortality in the Republic of Korea. Since the 2009 H1N1 pandemic, there have been increasing usages of antiviral agents for the treatment of patients with seasonal influenza. Although currently rare, antiviral resistance among influenza viruses may emerge and increase with increased use of neuraminidase inhibitors. New agents with different modes of action are under investigation, including favipiravir, DAS181, nitazoxanide and broad-spectrum neutralizing monoclonal antibodies. Data are limited with respect to high-dose and combination antiviral therapies. So, clinical trials are warranted to evaluate diverse antiviral combinations that may be synergistic and less likely to induce breakthrough resistance.

KW - Antiviral agents

KW - drug resistance

KW - epidemics

KW - influenza

KW - Republic of Korea

UR - http://www.scopus.com/inward/record.url?scp=84945448542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945448542&partnerID=8YFLogxK

U2 - 10.1586/14787210.2015.1076334

DO - 10.1586/14787210.2015.1076334

M3 - Review article

VL - 13

SP - 1361

EP - 1372

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 11

ER -